Core Viewpoint - Gain Therapeutics, Inc. has announced a public offering of 4,501,640 shares of common stock and warrants, aiming to raise approximately $7.0 million for the development of its lead product candidate GT-02287 and general corporate purposes [1][3][4]. Group 1: Offering Details - The public offering price is set at $3.11 for two shares of common stock and one warrant, translating to an effective price of $1.55 per share and $0.01 per warrant [1]. - The warrants will have an exercise price of $1.65 per share, are immediately exercisable, and will expire five years after issuance [1]. - The underwriter has a 30-day option to purchase up to an additional 15% of shares and/or warrants at the public offering price [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized for the clinical and nonclinical development of GT-02287, targeting neurodegenerative diseases such as GBA1 Parkinson's disease, as well as for general corporate purposes [4]. Group 3: Company Overview - Gain Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing next-generation allosteric therapies, with GT-02287 currently in a Phase 1b clinical trial for Parkinson's disease [7]. - The company employs its Magellan™ platform to discover novel allosteric small molecule modulators aimed at treating various difficult-to-treat disorders, including neurodegenerative diseases and rare genetic disorders [8].